Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
22. Januar 2025 08:00 ET
|
Lisata Therapeutics, Inc.
Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4...
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
15. Januar 2025 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment...
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
10. Dezember 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment...
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
03. Dezember 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
19. November 2024 08:30 ET
|
Lisata Therapeutics, Inc.
Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is devoted...
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12. November 2024 16:05 ET
|
Lisata Therapeutics, Inc.
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. ...
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
06. November 2024 09:23 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the...
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
06. November 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced...
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
31. Oktober 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced...
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
28. Oktober 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced...